Chrystelle Lamagna

Chrystelle Lamagna has worked in the field of biology for over two decades. Chrystelle began their career in 2000 as an undergraduate at Universite Aix-Marseille. In 2001, they began their Ph.D. studies at the University of Geneva, where they were awarded the Best Ph.D. in Biology Thesis Award in 2005. Chrystelle then completed two postdoctoral fellowships at UCSF, where they studied Lyn kinase signaling and autoimmunity, as well as the mechanism for neoplastic transformation of neural stem and progenitor cells. In 2014, they began their role at Rigel Pharmaceuticals Inc. as Executive Director of Biology, Director of in vivo Pharmacology, and Senior Scientist. In 2022, they joined Terray Therapeutics as Director of Translational Biology.

Chrystelle Lamagna earned their Ph.D. in Cell Biology and Immunology from the University of Geneva between 2001 and 2005. Prior to that, they obtained their Master's degree in Cell Biology, Immunology, and Microbiology from Aix-Marseille University between 1996 and 2001.